The biochemical investigation is descnbed of a boy who presented with precocious puberty at the age of 3 years 9 months due to a rare form of congenital adrenal hyperplasia (CAH), steroid 11~-hydroxylase deficiency. Serum androgen levels were grossly elevated (17 hydroxyandrogens 10 nrnol/l, androstenedione 129 nmolfl), 17 hydroxyprogesterone was modestly elevated (21 nmol/l), while serum gonadotrophins were low and testes were prepubertal in size. The major differential diagnosis was between an androgen-producing tumour and CAH. Initial serum and urine corticosteroid concentrations and their responses to dexamethasone were diagnostically misleading, later found to be due to lack of specificity of the radioimmunoassays and fluorimetric methods employed. Elevated basal plasma ACTH levels and suppression of androgen and ACTH levels by dexamethasone strongly suggested CAH. Definitive diagnosis of an II~-hydroxylase defect was established by capillary column gas liquid chromatography of urine which demonstrated excess androgen and 11-deoxycortisol metabolites but no cortisol metabolites. The diagnosis was confirmed by specific serum assays of II-deoxycortisol, deoxycorticosterone, and cortisol. The contribution of hormone assays and a protocol for their use in the diagnosis and monitoring of precocious puberty is discussed.
SUMMARY The biochemical investigation is descnbed of a boy who presented with precocious puberty at the age of 3 years 9 months due to a rare form of congenital adrenal hyperplasia (CAH), steroid 11~-hydroxylase deficiency. Serum androgen levels were grossly elevated (17 hydroxyandrogens 10 nrnol/l, androstenedione 129 nmolfl), 17 hydroxyprogesterone was modestly elevated (21 nmol/l), while serum gonadotrophins were low and testes were prepubertal in size. The major differential diagnosis was between an androgen-producing tumour and CAH. Initial serum and urine corticosteroid concentrations and their responses to dexamethasone were diagnostically misleading, later found to be due to lack of specificity of the radioimmunoassays and fluorimetric methods employed. Elevated basal plasma ACTH levels and suppression of androgen and ACTH levels by dexamethasone strongly suggested CAH. Definitive diagnosis of an II~-hydroxylase defect was established by capillary column gas liquid chromatography of urine which demonstrated excess androgen and 11-deoxycortisol metabolites but no cortisol metabolites. The diagnosis was confirmed by specific serum assays of II-deoxycortisol, deoxycorticosterone, and cortisol. The contribution of hormone assays and a protocol for their use in the diagnosis and monitoring of precocious puberty is discussed.
Puberty is considered to be precocious if it occurs before the age of 10 years in a boy and before the age of 8 years in girl. In pseudoprecocious puberty, secondary sexual characteristics develop without gonadal maturation whereas in true precocious puberty the child may be fertile. Accurate differential diagnosis is important because some causes can be treated effectively, but this can be achieved only if reliable hormone assays are available.
We describe the case of pseudoprecocious puberty in a boy aged 3 years 9 months, due to a rare form of congenital adrenal hyperplasia (CAH), steroid 11~ hydroxylase deficiency, which accounts for less than 4 %of cases of CAR. l 2 In this condition, conversion of l l-deoxycortisol (Compound S) and deoxycorticosterone (DOC) to cortisol and corticosterone respectively is impaired. The resulting ACTR hypersecretion gives rise to increased secretion of Compound S and DOC. Chronically elevated levels of the mineralocorticoid DOC may cause hypertension. Stimulation of alternative pathways of adrenal steroid biosynthesis also leads to overproduction of C,• steroids such as testosterone, dehydroepiandrosterone (DHA), and M-androstenedione (A 2 ) , resulting in virilisation.
We describe several pitfalls in interpreting steroid hormone assays in the diagnosis of this condition and assess biochemical methods of monitoring therapy. Finally, the contribution of hormone assays to the differential diagnosis of isosexual precocious puberty is reviewed.
Case history
A boy aged 3 years 9 months presented with a four-month history of development of secondary 145 sexual characteristics. Two older brothers were normal, and there was no evidence of consanguinity in the parents. The patient had had febrile convulsions since the age of 8 months, which were being controlled by phenytoin (Epanutin syrup 7·5 ml three times a day). On examination the penis was of adult proportions, pubic hair was present (stage 2 on the Tanner rating), the scrotum was well developed and the testes were prepubertal in size. Bone age was advanced (10 years) and he was above the 97th centile for both height (114 ern) and weight (20·8 kg). Blood pressure was 120/70, the systolic pressure being modestly elevated for his chronological age. A mild general skin pigmentation was noted although not in the buccal mucosa. Electrolyte concentrations were consistently within normal limits. On one occasion a mild fasting hypoglycaemia (glucose 2·1 mmol/l) was recorded at 0900 after an overnight fast. No significant abnormalities were found on skull x-ray, CAT scanning of the head and abdomen, abdominal ultrasound, and intravenous pyelography.
AFTER TREATMENT
After diagnosis treatment was started with cortisone acetate, 15 rng in the morning and 10 mg in the evening for three months, thereafter prednisolone, 2 rng in the morning and 3 rng in the evening. Convulsions associated with fever and upper respiratory infection occurred twice in the following year, otherwise clinical progress was uneventful. During the year of treatment growth slowed to 2·5 ern (normal about 7 ern) and weight gain to I· I kg (normal about 2 kg). Blood pressure averaged 105/65. Bone age after treatment for nine months remained advanced at II years. His personality, appearance, and secor.dary sexual characteristics were unchanged. Assay methods SERUM Serum 'cortisol' was determined by the f1uorimetric method of Mattingly," by radioimmunoassay (RIA) (Corning Immophase kit) and by gas-liquid chromatography (GLC).4 17-Hydroxyandrogens ('testosterone'), A 2 , ll-deoxycortisol (S),17or.-OH progesterone (170HP), oestradiol (E 2 ) l l-deoxycorticosterone (DOC), and corticosterone were assayed in serum extracts by RIA methods. Dehydroepiandrosterone sulphate (DHA-S0 4) was assayed directly in serum by RIA by a modification of the method of Smith et al. s Aldosterone was assayed by a RIA kit method (CIS).
Luteinising hormone (LH), follicle stimulating hormone (FSH), prolactin, human chorionic gonadotrophin (HCG), ACfH, '~-MSH', thyroxine (T4), Ratcliffe, McClure, Auld, Honour, Fraser and Ratcliffe and triiodothyronine (T3) were assayed by standard double-antibody RIA methods. URINE Cortisol was assayed by fluorimetry and RIA (Corning Immophase kit). 17-0xosteroids, 17oxogenic steroids, pregnanetriol, and II-oxygenation index were determined by standard methods. Urinary aldosterone was assayed by RIA following hydrolysis at pH 1·0.
Steroid conjugates in urine were hydrolysed before analysis by capillary column gas chromatography," Cortisol metabolites were analysed by computer processing of the data obtained by mass spectrometric analysis of the effluent from the gas chromatograph.
Results

BEFORE TREATMENT
Serum (Table 1) Thyroid function tests were normal. Basal gonadotrophins were within normal limits. After administration of gonadotrophin releasing hormone (100 flg iv) LH and FSH levels were <1·5, <1·5, <1·5, and <0·8,1·5, and 3.1 V/I, respectively, at 0,20, and 60 min. 17-0HP was marginally elevated although not within the range found in CAH due to a 21hydroxylase deficiency. 7 'Testosterone', A 2 , and DHA-S0 4 levels were grossly elevated. 'Cortisol' levels at 0900 were in general within normal limits by fluorimetry and RIA, although on one occasion a result of 140 nmol/I was obtained by fluorimetry. Fluorogenic 'cortisol' levels at 2100 and 0900 of 280 and 410 nrnol/l suggested the presence of a normal circadian rhythm. Subsequently, 'cortisol' determined by GLC was shown to be very low (40 nrnol/l), Compound S and DOC levels were grossly elevated while the corticosterone level was subnormal and at the limit of detection of the assay. Serum aldosterone concentration was low. Plasma ACTH and '~-MSH' levels were consistently elevated. High-dose dexamethasone (2 mg four times a day for two days) suppressed 'cortisol', ACTH, 'testosterone', A 2 , and DHA-S0 41evels significantly.
Urine (Table 2) When 'cortisol' was determined by fluorimetry the cortisol/creatinine ratio was elevated whereas by RIA the ratio was within normal limits. After highdose dexamethasone for two days, the cortisol/ creatinine ratio (by fluorimetry) suppressed normally, whereas when cortisol was assayed by RIA the ratio increased. This was subsequently shown to be due to cross-reaction of dexamethasone with the t2 mg dexamethasone qid for two days. antiserum employed in the cortisol RIA kit. Pretreatment 17-oxo and 17-oxogenic steroids were significantly elevated for age and suppressed on dexamethasone.
The urinary steroid profile assayed by GLC indicated that the major steroids present were metabolites of Compound S and androgens (Table  3 ). Mass spectrometry of the column effluent indicated complete absence of cortisol metabolites.
AFTER TREATMENT
Serum (Table 1) Androgen levels suppressed slowly on therapy, becoming normal after 12 months. Compound Sand DOC levels fell to normal and corticosterone and cortisol (by GLC) became undetectable. Aldosterone levels remained low. Plasma ACTH levels before morning replacement therapy were not significantly elevated. 
Urine
Fluorogenic 'cortisol' levels were markedly reduced though 17-oxosteroids remained marginally elevated for six months. Aldosterone levels remained low.
Discussion
DIFFERENTIAL DIAGNOSIS
The differential diagnosis of precocious sexual development in boys includes the conditions listed in Table 4 . In the present case, gonadotrophindependent causes were excluded, as gonadotrophin levels were low and unresponsive to gonadotrophin releasing hormone, RCG was undetectable and the testes were prepubertal in size. The normal skull x-ray and CAT scan also argued against an intracerebral space-occupying lesion despite the clinical The differential diagnosis thus centred on an androgen-producing tumour of either adrenal or gonadal origin and congenital adrenal hyperplasia. The grossly elevated androgen levels were considered to be compatible with a steroid-producing tumour though there was no clinical evidence of a gonadal tumour, and abdominal CAT scan and ultrasound failed to identify an adrenal tumour. Furthermore, serum 17-0HP and urine pregnanetriollevels, which are widely used as screening tests for the most common variety of CAH (21-hydroxylase defect), were not diagnostic, serum 'cortisol' levels by fluorimetry and RIA were normal with preserved circadian rhythm, and urine 'cortisol' and I7-oxogenic levels were difficult to interpret. Other potential clinical features of CAR were not evident: blood pressure was not clearly elevated nor were serum electrolytes abnormal though it is significant in retrospect that mild fasting hypoglycaemia was recorded on one occasion.
However, strong evidence in favour of CAR came from the consistently elevated plasma ACTH and '~MSH' levels and suppression of urinary fluorogenic 'cortisol' and serum androgens by high-dose dexamethasone although the failure of suppression of urinary immunoactive 'cortisol' was puzzling. The diagnostic dilemma was solved definitively by the profile of steroid metabolites obtained by capillarycolumn gas chromatography. No cortisol metabolites were found, whereas there were grossly elevated levels of metabolites of Compound S and androgens, thus clearly establishing the diagnosis as congenital adrenal hyperplasia due to an 11~-hydroxylase defect. This was confirmed subsequently by the low serum cortisol level (measured by a highly specific method involving oxidation of cortisol before derivatisation and followed by GLC with electron capture detection) and the grossly elevated levels of S and DOC with low corticosterone levels (measured by specific RIA).
In retrospect it is evident that the apparently normal serum and urine 'cortisol' levels were interpreted incorrectly, leading to delay in achieving the correct diagnosis. Although the Mattingly technique is well known to measure corticosteroids other than 'cortisol', the lack of specificity in many current RIA methods for cortisol is less well appreciated. A summary of the cross-reaction of S and DOC in some kit and literature methods is given in Table S. The kit used in the present study cross-reacts 11 % with S, so that the observed concentration of this steroid (820 nmol/I) may have contributed about 90 nmol/l to the serum 'cortisol' measurement. The increase in urinary free 'cortisol' measured by RIA during the dexamethasone suppression test is particularly notable since it is generally accepted that this analogue does not interfere in the f1uorimetric method. In fact it was shown that dexamethasone cross-reacted significantly in the Corning kit method.
MONITORING THERAPY
On replacement therapy, levels of ACTH, DOC, S, A 2 , and 'testosterone' were suppressed to normal. Since levels of I7-0HP are not clearly elevated in II-hydroxylase deficiency, monitoring with I7-0HP is less satisfactory than in 21-hydroxylase deficiency, where its role is well established. Serum A 2 has been proposed as the single androgen best reflecting control.!' whereas urine I7-oxosteroids provide an index of overall daily androgen excretion. In our patient, androgen output was monitored by serum A 2 , 'testosterone', and urine 17-oxosteroids, and glucocorticoid status by plasma ACTH levels before the morning dose of prednisolone.
Mineralocorticoid status during therapy is of particular interest since aldosterone levels were subnormal before treatment and aldosterone and corticosterone levels remained low after treatment. Despite this, mineralocorticoid replacement appears to be unnecessary in our patient at present, providing a normal salt intake is maintained. In cases of 11hydroxylase deficiency where aldosterone levels have become normal after treatment, Levine et al 12 proposed that the defect was localised in the fasciculata, activity in the glomerulosa being unaffected. In the untreated patient low aldosterone levels are thought to result from suppression of plasma renin activity by high DOC levels originating from the In the light of the present case, we have reviewed our investigation of suspected cases of precocious puberty in boys. Assuming that iatrogenic causes and secondary causes such as hypothyroidism are excluded initially, we suggest the following sequence of hormone assays to complement clinical and radiological investigations. Stage 2 Distinguish a tumour of adrenal or testis andCAH Basal levels of DHA-S0 4 , A 2 , 17-0HP, and ACTH and the corticosteroid response to dexamethasone suppression. These tests are available in regional hormone laboratories or through the Supraregional Assay Service in England and Wales or the Immunoassay Support Service in Scotland.
Cross-reaction (cortiso/=]OO %)
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Stage 3 Identify the enzyme defect in CAH
The profile of urinary steroids by gas liquid chromatography or the specific assay of adrenal steroids such as cortisol, S, DOC, and corticosterone. These tests are available only in specialised centres by arrangement and should therefore be restricted to rare cases in which the identification of an enzyme defect is required in detail.
